RAPT THERAPEUTICS INC
COM · CUSIP 75382E109
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $8.00.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 98 |
| Q4 2022 | 96 |
| Q1 2023 | 107 |
| Q2 2023 | 99 |
| Q3 2023 | 97 |
| Q4 2023 | 110 |
| Q1 2024 | 123 |
| Q2 2024 | 104 |
| Q3 2024 | 95 |
| Q4 2024 | 92 |
| Q1 2025 | 93 |
| Q2 2025 | 2 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2023 | 42 | 43 |
| Q4 2023 | 56 | 44 |
| Q1 2024 | 71 | 54 |
| Q2 2024 | 51 | 69 |
| Q3 2024 | 37 | 44 |
| Q4 2024 | 54 | 52 |
| Q1 2025 | 43 | 39 |
| Q2 2025 | 0 | 91 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2024 | $119.8k | $4.8k | 0.04 |
| Q4 2024 | $507.1k | $364.8k | 0.72 |
| Q1 2025 | $61.1k | $122 | 0.00 |
| Q2 2025 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| Medicxi Ventures Management (Jersey) Ltd | Sold out | -22.4m |
| ORBIMED ADVISORS LLC | Sold out | -13.1m |
| TCG Crossover Management, LLC | Sold out | -13.1m |
| Foresite Capital Management VI LLC | Sold out | -12.5m |
| RTW INVESTMENTS, LP | Sold out | -11.8m |
| BVF INC/IL | Sold out | -9.2m |
| VANGUARD GROUP INC | Sold out | -8.3m |
| Redmile Group, LLC | Sold out | -6.5m |
| Deep Track Capital, LP | Sold out | -6.0m |
| ADAR1 Capital Management, LLC | Sold out | -6.0m |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Medicxi IV LP 13G · passive investor new · filed 2025-01-06 | 16.9% |
| TCG Crossover GP II, LLC 13G · passive investor new · filed 2025-01-03 | 10.0% |
| Redmile Group, LLC 13G · passive investor filed 2025-02-14 | 9.9% |
| Deep Track Capital, LP 13G · passive investor new · filed 2024-12-23 | 9.9% |
| Foresite Capital Fund VI LP 13G · passive investor new · filed 2024-12-30 | 9.3% |
| RTW INVESTMENTS, LP 13G · institution new · filed 2025-05-15 | 8.9% |
| VANGUARD GROUP INC 13G · institution +4.0 pts · filed 2025-04-30 | 6.3% |
| GLAZER CAPITAL, LLC 13G · passive investor new · filed 2026-02-09 | 5.4% |
Fell to 5% or below in the last year: ORBIMED ADVISORS LLC (0.0%, 2026-05-15), BIOTECHNOLOGY VALUE FUND L P (0.0%, 2025-11-14)
Holders, Q2 2025
| Manager | Shares | Change |
|---|---|---|
| Column Group LLC 16.17% of their portfolio | 1.3m $10.6m | Unchanged |
| AJU IB Investment Co., Ltd. 0.11% of their portfolio | 12.4k $99.5k | Reduced -87.1k |